Results 71 to 80 of about 19,663 (194)
Administration of crizotinib via jejunostomy tube: A case report
, 2018 Crizotinib is an orally available tyrosine kinase inhibitor, approved for treatment of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangement-positive non-small cell lung cancer (NSCLC).
Knapen, Lotte +2 more
core +1 more source
EBioMedicine, 2019 Background: Crizotinib has potent anti-tumor activity in patients with advanced MET-amplified non-small cell lung cancer (NSCLC). However, the therapeutic effect is still not satisfying. Thus, developing approaches that improve the efficacy of crizotinib
Zhen Liu +10 more
doaj +1 more source
International Journal of Cancer, Volume 159, Issue 10, Page 2606-2618, 15 November 2026.ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at ...
Tillmann Bedau +7 more
wiley +1 more source
, 2015 Red arrows represent the direction of the crizotinib escaping from the binding pocket. The yellow region denotes the necessary bin ding channel for (R)-crizotinib escaping out of the active pocket, and the green region represents the important residue ...
Qifeng Bai (220551) +5 more
core +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3656-3665, October 2026.Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson +8 more
wiley +1 more source
Crizotinib-Induced Abnormal Signal Processing in the Retina. [PDF]
, 2015 Molecular target therapy for cancer is characterized by unique adverse effects that are not usually observed with cytotoxic chemotherapy. For example, the anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor crizotinib causes characteristic visual ...
Akemi Maeda +5 more
core +1 more source
The Role of Chemotherapy in Pediatric Myoepithelial Carcinoma: A Systematic Review of the Literature
Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.ABSTRACT Myoepithelial carcinoma (MEC) in pediatric patients is a rare and aggressive malignancy characterized by heterogeneous morphology and variable molecular features. The optimal role of chemotherapy remains unclear. We conducted a systematic review according to PRISMA 2020 guidelines to evaluate chemotherapy in pediatric and young‐adult patients ...
Marco Salvi +7 more
wiley +1 more source
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
, 2018 Laura Mezquita, David Planchard Medical Oncology Department, Gustave Roussy, Villejuif, France Abstract: Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years ...
Mezquita L, Planchard D
core
Zhongguo aizheng zazhi, 2015 Background and purpose: Although crizotinib could manifest marked antitumor activity in anaplastic lymphoma kinase (ALK)-rearrangement-positive non-small cell lung cancer (NSCLC) patients, but brain metastases is always occured in such patients.
黄伟, 王琳, 秦叔逵
doaj
Cost Effectiveness and Resource Allocation, 2020 Introduction Lower-dose ceritinib (450 mg) once-daily with food was approved in 2018 in Hong Kong (HK) for first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK +) advanced non-small cell lung cancer (NSCLC).
Herbert H. Loong +7 more
doaj +1 more source